← Dashboard

Compliance Alert: Use and Important Safety Information

Configure Methodology
78
Lower Risk
This ISI content is within acceptable compliance thresholds.

Analysis of this 110s ISI content identified no enforcement patterns against 14 known violation categories.

Recommended action: Flag for next MLR cycle: Benefit-to-risk presentation balance requires attention. Ensure risk information receives comparable prominence, duration, and audio/visual treatment.

Use and Important Safety Information | Attruby| BridgeBio Pharma, Inc. | ISI
DOC-2025-001244 Mar 10, 2026
78
Master
95
Visual
30%
75
Efficacy
15%
50
Fair Balance
15%
ISI thresholds
75
Adeq Prov
10%
ISI thresholds
--
Lifecycle
10%
Video Timeline
Risk disclosure: 33.0s – 83.7s (50.7s of 109.7s total — 46.2% of ad)
Risk Window
0s27s55s82s110s
No visual distractions detected
Risk Window?The portion of the ad where side effects and safety warnings are narrated. Distracting visuals during this window are an FDA enforcement priority.

Recommendations

high
Flag for next MLR cycle: Benefit-to-risk presentation balance requires attention. Ensure risk information receives comparable prominence, duration, and audio/visual treatment.
▶ Full Video Preview 1:50 · ISI
Use and Important Safety Information
ISI
Duration: 1:50 Alert: ATT-2026-0001
Veeva PromoMats Details
Synthetic data for demonstration purposes. In production, this section is populated from Veeva PromoMats via API integration.
Document ID
DOC-2025-001244
Status
Approved for Distribution
Version
1.0
Content Type
Celebrity Endorsement
MLR Review
Jun 18, 2025
Next Review Due
May 20, 2026 (70d)
Talent Expiration
Dec 1, 2025 (Expired)
Music License
Jun 1, 2026 (82d)

Powered by cQuenced